{{Rsnum
|rsid=2289669
|Gene=SLC47A1
|Chromosome=17
|position=19560030
|Orientation=plus
|GMAF=0.343
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC47A1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 18.6 | 54.0 | 27.4
| HCB | 21.2 | 52.6 | 26.3
| JPT | 19.6 | 42.9 | 37.5
| YRI | 0.0 | 0.0 | 100.0
| ASW | 1.8 | 17.9 | 80.4
| CHB | 21.2 | 52.6 | 26.3
| CHD | 27.5 | 41.3 | 31.2
| GIH | 18.0 | 53.0 | 29.0
| LWK | 0.0 | 3.6 | 96.4
| MEX | 22.4 | 53.4 | 24.1
| MKK | 1.9 | 21.2 | 76.9
| TSI | 16.7 | 52.9 | 30.4
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19898263
|Title=Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
}}

{{PMID Auto
|PMID=21241070
|Title=Clinical pharmacokinetics of metformin
}}

{{PMID Auto
|PMID=19074986
|Title=Expansion of human regulatory T-cells from patients with type 1 diabetes.
|OA=1
}}

{{PMID Auto
|PMID=19228809
|Title=Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
|OA=1
}}

{{PMID Auto
|PMID=22569819
|Title=Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
}}

{{PMID Auto
|PMID=22882994
|Title=Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}